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An extensive literature has developed relating the effects of the various
antihistamine drugs on the course of dermatoses thought to be based on the
mechanism of allergy. Their oral, as well as parenteral administration, has had
definite therapeutic effects on those skin eruptions which, like urticaria, have an
element of whealing in their pathology (1—7). In dermatoses with mainly epi-
dermal pathology, both allergic and non-allergic in nature, the effects of the
antihistamine drugs have varied with the mode of administration. The pruritic
element seems to be the factor chiefly affected where beneficial therapeutic
results were obtained (8—10).
With the introduction of ointments containing histamine antagonists, further
evaluation of their therapeutic action has been made in many dermatoses (11—15).
The pharmacology of the antipruritic effect of the antihistamine drugs is as yet
little understood. There is the possibility, however, that in these topical applica-
tions the ointments act only partly in a manner similar to a local anesthetic.
That is well demonstrated in the experiments of Mayer (15) and Aaron, Peck
and Abramson (16).
The therapeutic results with topical application of antihistamine drugs in the
form of ointments have varied widely not only in skin eruptions of differing
pathology, but in different patients with the same skin disease or even in the
same patient at different stages of the eruption. Naturally, the question of
absorption of the antihistaminic substance through the skin comes into the
foreground in such instances.
In this study, we have attempted to evaluate the effects on histamine whealing
and allergic epidermal reactions of the administration of Pyribenzamine by oral
and parenteral administration, as well as by iontophoresis and the application of
Pyribenzamine ointment. Quantitative excretion studies of Pyribenzamine after
topical application were made in an attempt to correlate the clinical action of
this drug administered in this way with the question of absorption through the
skin. The results of these experiments also explain the variability in antipruritic
as well as other effects with ointments containing Pyribenzamine.
* From the Dermatologic Laboratory and Chemistry Department of The Mount Sinai
Hospital, New York City.
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EXPERIMENTAL
Effects on the histamine wheat of various routes of administration of Pyribenzamine
The histamine wheal was produced by the intradermal injection of 0.05 cc.
of histamine phosphate solution diluted 1:10,000. The flexor surface of the fore-
arm or the extensor surface of the arm was used.
TABLE I
PYRI-
BENZA-
MINE:
RISTA-
MINE-
NT IN-
ORAL ADMINISTRATION
(400 MG. DAILY FOR 3 DAYS)
0.05 cc. of 1:10,000 so!.
LOCAL INjECTION (2 cc. (50 MG.))
AFTER ONE HOUR: 0.05 cc. o
1:10,000 SOL.
IONTOPHOESIS 5%
PYRIBENZAMINE SOL.
AFTER 24 HouRs: 0.5 cc. OF
1:10,000 Soi..
yECTION
W 0.9 x 1.0 W 1.2 x 2.0 W 0.6 x 0.4 W 1.2 x 2.0 W 0.9 x 1.2 W 1.2 x 2.0
F 4.0 x 4.0 F 4.0 x 5.0 F 2.2 x 2.0 F 4.0 x 5.0 F 2.5 x 2.5 F 4.0 x 5.0
W1.5x1.5 W1.3x2.0 W0.7x0.8 W1.3x2.0 W0.6x0.7 W1.3x2.0
F 4.0 x 4.0 F 4.5 x 5.0 F 2.5 x 2.5 F 4.5 x 5.0 F 2.5 x 3.0 F 4.5 x 5.0
WO.8x1.2 W1.2x1.4
F 3.0 x 4.3 F 5.0 x 6.0
W0.7x1.1 W1.3x1.5
F 1.5 x 2.5 F 4.0 x 5.0
W1.Oxl.1 W1.2x1.6
F 3.5 x 5.5 F 3.0 x 4.0
W0.6x0.9 W1.Oxl.5
F 3.0 x 3.5 F 4.0 x 5.0
Oral administration. In six patients, the whealing response to the histamine
injections was determined. The patients were then given 400 mgm. of Pyri-
benzamine by mouth daily in divided doses for three days. On the fourth day,
analogous areas of skin, not previously used, were retested with the histamine.
Effect on hi8t amine wheat and flare of various route8 of administration of Pyribenzamine
After treatment
W 1.0 x 1.2
F 2.0x2.5
Control
W 1.0 x 1.2
F 2.2x2.5
Treated area
W 0.9 x 1.0
F 1.2x1.5
Control
W 1.0 x 1.0
F 2.2x2.5
W1.Oxl.0 W1.2x2.5 W0.6x0.7 W1.2x2.5
F 3.0 x 3.5 F 4.0 x 5.0 F 1.2 x 1.2 F 4.0 x 5.0
Treated area
W 1.0 x 0.9
F 1.2x1.2
W 0.8 x 1.0
F 3.0x3.5
Control
W 1.0 x 1.2
F 2.2x2.5
W 1.2 x 2.5
F 4.0x5.0
Sub-
jects
1.w.
2. M.
3. W.
4. B.
5. L.
6. G.
7. K.
8. L.
9. U.
W 0.6 x 0.7
F 1.2 ,c 1.2
W 1.5 x 2.0
F 2.5x2.5
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Results: As was to be expected and has been shown by others (1—4), there was a
diminution in the wheal and flare in most instances (Table I).
Local injections. In five subjects, four of whom were used in the previous
experiments, the effects of local injection of Pyribenzamine on the histamine
wheal were studied.
An area of skin, 5 centimeters in diameter on the flexor surface of the forearm
was injected with 2 cc. of Pyribenzamine hydrochloride solution containing 50
mgm. of the drug. The injections were made subcutaneously in divided doses so
that equal amounts were injected in the center and at four points equidistant
from the center. One hour after the injection, the histamine wheal was made in
in the injected areas as well as in the same site on the other arm.
Results: In all patients, the whealing and the flare were reduced in the in-
jected area (Table I).
lontophoresis. lontophoresis was performed with 5% Pyribenzamine hydro-
chloride solution in a manner previously described (16—18). An area of skin
approximately 5 centimeters in diameter on the flexor surface of the forearm
was prepared in six patients. Twenty-four hours after the iontophoresis, a
histamine injection was made in the iontophoresis area as well as in a comparable
control site.
Results: The wheal and flare were diminished in all instances in the area of
iontophoresis (Table I).
Ointment. (a) In this experiment, the standard Pyribenzamine ointment was
used. It contains 2% Pyribenzamine hydrochloride in a petrolatum base. Three
grams of the ointment were rubbed into an area of skin approximately 10 centi-
meters in diameter until the ointment had practically disappeared. The rubbing
was always continued for five minutes. It was found that more than this amount
of ointment failed to rub in completely. The flexor surface of the forearm or the
extensor surface of the arm was used. Approximately 5 minutes after the appli-
cation of the ointment, histamine injections were made in the treated area and
in a control site.
Results:
TREATED AREA CONTROL ATEA
PatientM. Wheal
Flare
cm.
1.0x2.0
3.5x4.0
cm.
W1.2x2.5
F4.0x5.0
Patient W. Wheal
Flare
1.0 x 1.0
4.0x4.O
W 1.2 x 2.0
F4.0x5.O
(b) In the same two patients, several days later, additional sites were pre-
pared as above with Pyribenzamine ointment. Twenty-four hours later, the
histamine wheal was made in the center of the treated area and in a control site.
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Results:
TREATED AREA CONTROL ARE!.
cm. cm.
PatientM. W
F
1.3x2.0
4.0 x 4.0
W
F
1.2x2.5
4.0 x 5.0
PatientW. W
F
0.9x1.0
3.0 x 5.0
W
F
1.2x2.0
4.0 x 5.0
(c) Two patients were used in this experiment. Three grams of the ointment
were rubbed into an area of skin 10 centimeters in diameter on three successive
days. Twenty-four hours later, a histamine wheal was made in the treated area
and in a control site.
Results:
TREATED AREA CONTROL AREA
cm. cm.
PatientJ.N. W
F
1.2x1.0
4.0 x 5.0
W
F
1.7x1.5
5.5 x 6.0
PatientJ.K. W
F
1.Oxl.2
5.0 x 5.5
W
F
1.2x2.0
5.0 x 6.5
Effects of various routes of administration of Pyribenzamine on reactions
of epidermat sensitivity
Experiment I
Patient G., known to be sensitive to adhesive tape, was used in this experi-
ment. After 24 hours of application, Bay adhesive gave a vesicular reaction.
lontophoresis: (a) As in the previous experiments, iontophoresis was done with
5% Pyribenzamine solution. After 24 hours, the adhesive was applied to the
area of iontophoresis and at a control site 3 centimeters below the area of
iontophoresis. Both patches were left on for 24 hours.
Results: There was only moderate erythema when the adhesive was removed
from the area where iontophoresis had been done. In the control site, there was
some erythema with a few papules. Evidently, there was still some effect of
Pyribenzamine iontophoresis 3 centimeters below the area where iontophoresis
was applied.
(b) The adhesive was reapplied to the area of iontophoresis eight days after
the above experiment had been made. A similar patch of adhesive was also
applied to a control site.
Results: The control site showed a vesicular reaction. The adhesive reaction
in the area of iontophoresis was less than at the control site, but still showed
erythema, papules and a few vesicles.
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(c) An area of skin was prepared with 2% novocaine iontophoresis. Adhesive
was applied to the area of iontophoresis and at a control site on the other arm.
Results: Both areas showed four plus reactions to the adhesive.
Local injections: (a) An area of skin 5 cm. in diameter was infiltrated subcu-
taneously with 2 cc. of Pyribenzamine solution containing 50 mgm. as in the
previous experiments. After 24 hours, adhesive was applied to this area and at a
control site for 24 hours.
Results: Both areas showed a four plus reaction.
(b) An area of skin 5 cm. in diameter was infiltrated with 2 cc. of novocaine
solution. After 24 hours, adhesive was applied to this area as well as to a control
site.
Results: Both areas showed a four plus reaction.
Ointment: Three grams of Pyribenzamine ointment were rubbed into an area
on the flexor surface of the forearm, 10 cm. in diameter, for 5 minutes. This was
repeated 3 times daily for 3 days. Ten minutes after the last application, the
surface of the skin was cleansed of remaining ointment and adhesive was applied
for 12 hours to the prepared site and over a control area.
Results: Both patches gave a four plus reaction.
Experiment II
Patient G., strongly sensitive to paraphenylenediamine, was the subject used.
Oral administration: The patient was given 400 mgm. of Pyribenzamine
daily, in divided doses, for three days. Eight hours after the last dose, he was
patch tested with paraphenylenediamine.
Results:
Patch tests 1 % paraphenylenediamine 3 to 4 plus
0.1 % paraphenylenediamine 2 pIus
0.01% paraphenylenediamine Negative
lontophoresis: Four days later, in the same patient, an area on the right arm
was prepared by iontophoresis with Pyribenzamine solution in the usual way.
Twenty-four hours later, patch tests were made over the area of iontophoresis
as well as at a comparable site. They were left on for 24 hours and then read.
Results:
lontophoresis area 1 % paraphenylenediamine 2 pIus
0.1 % paraphenylenediamine 1 to 2 plus
0.01% paraphenylenediamine Negative
Control area 1 % paraphenylenediamine 2 to 4 plus
0.1 % paraphenylenediamine 2 to 3 plus
0.01% paraphenylenediamine Negative
Local injections: An area of skin 5 cm. in diameter was prepared with sub-
cutaneous injections of Pyribenzamine hydrochloride, 2 cc. containing 50 mgm.
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as in the previous experiments. Patch tests were made with paraphenylenedi-
amine over the area of injections and at a control site.
Results:
INJECTED SITES CONTROL SITES
1 %3to4plus 1 %3to4plus
0.1
0.0
%2plus
1% Negative
0.1
0.0
%2plus
1% Negative
Quantitative determination of urinary excretion of Pyribenzamine after topical
application to normal and damaged skin
In view of the variability of the chemical effects of Pyribenzamine ointment
and since it seems to effect histamine whealing but not the reaction of epidermal
sensitivity, it was considered of interest to study the question of absorption of
Pyribenzamine through the skin following topical application. A method of
study presented itself in the analytical procedure of Perlman (19) for the fluoro-
metric determination in urine of minute amounts of Pyribenzamine and related
antihistamine compounds containing the pyridine radical.
For instance, it hs been shown by Gelvin et al. (20) that about 20% of a
single dose of 400 mgm. of Pyribenzamine given by mouth, may be recovered in
the urine. Perlman, by his chemically more specific method, recovered about
10% after oral administration, or after intravenous injection; following ion-
tophoretic application of Pyribenzamine to the normal skin, Pyribenzamine was
detectable in small amounts only after 18 hours.
METHOD
Since we expected a high dilution of the drug in the urine following external
application, we modified Perlman's method by extracting instead of 5 ml.
aliquots of the hourly urine specimens, either the total specimen or at least 50
ml. aliquot. The extraction of the alkalinized urine with an equal amount of
benzene was carried out in 125 ml. separatory funnels, which could be centrifuged
whenever persistent emulsions had formed. The addition of a few drops of caprylie
alcohol was also helpful in breaking such emulsions. The benzene extract was
evaporated in the vacuum of an aspirator pump to about 1 ml. This concentrate
was washed with benzene into glass-stoppered centrifuge tubes to a volume of
4 ml. and was, from there on, treated with normal 1101 and the other reagents
as in the original method.
The method was checked by adding known amounts of Pyribenzamine to 50
ml. normal urine, which was then carried through the entire procedure. The
recoveries were 87 to 92 per cent. In separate experiments, it was shown that the
boiling of the urine with alkali did not impair the recoveries.
Results of experiments: Ten grams of Pyribenzamine ointment were rubbed,
for ten minutes with rubber gloves, onto the thigh or forearm of three healthy
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young individuals with unbroken skin. There was a total of 200 mg. of Pyri-
benzamine in the ointment. The area was kept covered with gauze for 1 hours.
Urine specimens were taken immediately before, and every hour after appli-
cation, for nine consecutive hours. The fluorophotometric analysis showed the
complete absence of Pyribenzamine. The sensitivity of the method is such that
the presence of more than 1 to 2 micrograms per specimen would have been
detected.
TABLE II
Excretion of Pyribenzamine in urine after application of Pyribenzamine ointment to
damaged skin
(Expressed in micrograms)
PATIENT
N. W. (male) B.R. (female) A. S. (female)' H. K. (male)
HOURS ATTER
APPLICATION: Diagnosis
Contact dermatitis Ery. Psoriaticum Neurodermatitis Infctious Jczematoid(severe) (mod. infiltration) (mod, infiltration) hOd.
0 (110) 0 0 0
0—1 250 10 6
1—2 170 5 13 70
2—3 260 16 15
3—4 500 30 50
4—5 720 No. spec. 27 570
5—6 740 21 48
6—7 670 17 58
7—8 340 17 63 410
8—9 400 19 —
9—12 — — —
Total
for 9 hrs 4160 135 280 1050
* Patient used Thephorin ointment day before day of test. Urine extract cloudy, did
not interfere with this test.
The same procedure was carried out in a patient with contact dermatitis. Ten
grams of the ointment were rubbed over the dermatitis on the forearm. This
man had received Pyribenzamine orally for three days, but this medication had
been interrupted 24 hours prior to the application of the ointment. His urinary
excretion immediately before the ointment was applied was 110 micrograms in
the early morning specimen. The excretion in the nine consecutive hours follow-
ing application of the Pyribenzamine is shown in Table II; they total 4160
micrograms for this period with the peak excretion during the fifth to seventh
hour. This amount (after a minor correction of approximately 80 micrograms
for the tail-end of the excretion due to previous oral Pyribenzamine therapy)
corresponds to 2% of the Pyribenzamine in the ointment.
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In another patient, B.R., who had erythroderma psoriaticum, and who had
not received Pyribenzamine previously, the ointment was similarly applied over
the eruption on the forearm. She excreted between the second and ninth hour
from 5 to 30 micrograms per sample, a total of 135 micrograms with the maxi-
mum in the fourth hour. This represents less than 0.1% of the amount applied.
Urine determinations of Pyribenzamine excretion were carried out in two
other patients. In patient, A. S., with a generalized neurodermatitis, the oint-
ment was applied to an area of dermatitis; a similar amount of ointment was
applied to an area of dermatitis in patient, H. K., who was considered to have
infectious eczematoid dermatitis. They excreted 280 and 1050 micrograms re-
TABLE III
Excretion of Pyribenzamine in urine after iontophoresis of Pyribenzamine on normal skin
SUBJECT TOT. VOl.. 22 HRS. MICROGRAMS DRUG EXCRETED IN URINE
5 % sol. P.B.Z.—10 milleamps.—120 sq. cm. for 15 minutes.
J. J. G.
R. M. B.
tnt.
1750
930
/ml. hot.
0.106 181.790
(N.B.: 15 mule-
amps)
0.0932 86.616
5% sol. P.B.Z.—10 milleamps.—96 sq. cm. for 10 minutes (once an hour for three hours on
three different sites on the back.)
J J. G. 1095 0.122 133.590
* There is a 10% factor of error in determining the results.
J. J. G.—subject became sleepy after iontophoresis which is further proof of adequate
absorption.
spectively during the eighth or ninth hours following application of the ointment,
corresponding to 0.06 and 0.14% of the amount of the drug. In patient, H. K.,
the test was extended to the twelfth hour; in the fourth three hour period, the
excretion had decreased further to 325 micrograms (Table II).
Quantitative determination of urinary excretion of Pyribenzamine after
iontophoresis to normal skin
As in previous experiments, the iontophoresis was carried out with 5% Pyri-
benzamine solution. Three subjects with normal skin, two males and one female,
were used in the experiments. In two of the subjects, the active electrode covered
an area of 120 square cm. The iontophoresis was carried out once for a period of
15 minutes. The forearm was used in each instance. In the third subject, the
active electrode covered an area of 96 square cm. The iontophoresis was carried
out for 10 minutes each time for three applications. Three different sites of the
back were used at hourly intervals. The Pyribenzamine excreted in all of the
urine voided for 22 hours after the iontophoresis in each of the three cases was
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determined. It can be seen from Table III that Pyribenzamine could be re-
covered from the urine after the iontophoresis on normal skin.
DISCUSSION
A further understanding of the clinical effects of Pyribenzamine in the various
dermatologic diseases can be gleaned from these experiments. There is some indi-
cation that the amount and the manner of administration of Pyribenzamine are
the most important factors in accomplishing the desired result. The most im-
portant single factor is that the drug has to be delivered in proper concentration
at the site where the clinical manifestations are present.
We wish to emphasize that only broad deductions can be made from our ex-
periments since it is not possible to adequately control all of the possible factors
of error. However, the results of the work which we have presented parallel
clinical experience enough to draw some conclusions.
The antihistaminics, particularly Pyribenzamine, have been used long enough
to establish clinically that the urticarial type of lesions responds fairly well to
their oral administration. A number of years ago, Baer and Sulzberger briefly
reported on the diminution of dermographism following the use of Pyribenzamine
under experimental conditions. We have attempted to determine the best method
of administration of Pyribenzamine for urticaria using the effect on the histamine
wheal and flare as our criterion for efficacy.
Under our experimental conditions, oral administration of Pyribenzamine
effected the histamine reaction less than either local injections of the drug or its
administration by iontophoresis. All this means is that a greater concentration
of Pyribenzamine at the histamine reaction site was obtained by the last two
methods of administration of the drug.
It can be seen that the application of Pyribenzamine ointment had relatively
little effect on the histamine wheal and flare. It is a common clinical experience
that applications of Pyribenzamine ointment or other antihistaminics in oint-
ment form were practically useless in the control of pruritus due to urticaria or
related lesions. Such observations are explained by our findings regarding Pyri-
benzamine excretion after application to normal skin. Very little if any of the
Pyribenzamine is absorbed through intact epidermis. Even if there is a moderate
depot effect, it certainly is inadequate both clinically and experimentally to
sufficiently effect urticarial reactions. The lesson we can learn, therefore, is that
when we attempt to influence urticarial or urticarial-like lesions, the best mode
of administration is certainly not topical application in ointment form.
We are confronted with an entirely different problem when we attempt to in-
fluence sensitivity reactions which have their main seat in the epidermis. Does
the administration of Pyribenzamine orally or by injection result in a deposit of
the drug in the epidermis? Does the Pyribenzamine which is administered in this
manner, find its way into the epidermis from below in sufficient concentration to
influence epidermal reactions?
Clinically, it has been the experience of most workers that the oral, intra-
muscular and subcutaneous administration of antihistaminics have very little
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influence on the course of epidermal sensitivity. In most instances, even the
pruritus which one could consider to be partly due to a pathology in papillary
bodies, is not even influenced to any extent if at all. Our experiments seem to
support the clinical observations.
We were unable to influence reactions of sensitivity to adhesive tape or para-
phenylenediamine as exemplified by patch tests, either by the oral administra-
tion of Pyribenzamine or by local injections of the drug. Since we could definitely
reduce sensitivity reactions by means of Pyribenzamine iontophoresis, we must
conclude that either none of the Pyribenzamine reaches the epidermis when
administered orally or by local injections; or if it did, it was in insufficient con-
centrations under our experimental conditions. The application of Pyribenza-
mine ointment to the unbroken skin was similarly ineffective. This is further
proof that there is little if any penetration of the drug from ointments into the
intact epidermis.
Once the skin is damaged, Pyribenzamine readily finds its way through the
skin. This supported by the clinical results in various dermatoses and by the
demonstration of adequate amounts of Pyribenzamine in urine after applica-
tions of ointment to the damaged skin. The amount of penetration will depend,
no doubt, on the degree and the type of damaged skin present.
It was not possible to use the patch test method to study the effects of oint-
ment application to damaged skin to see if there was any possible decrease in
sensitivity.
A valid criticism of the interpretation of our iontophoresis experiments on
epidermal sensitivity would be that, perhaps, non-antihistaminics might react
as well as Pyribenzamine to decrease epidermal reactions. Our experiments with
novocaine iontophoresis answer this question, since iontophoresis with novocaine
which is known to penetrate the epidermis sufficiently to give local anesthesia,
failed to influence patch test reactions.
Previous Pyribenzamine iontophoresis to normal skin is apparently able to
diminish reactions of epidermal sensitivity. This effect lasts for varying lengths
of time. In our first paper, we reported that the reduction of epidermal sensitiza-
tion reactions persisted for a number of weeks after the iontophoresis. One of the
authors (S. P.) has attempted to protect the hands of dentists from allergic con-
tact dermatitis due to nickel, novocaine and other allergens. Not only could
reactions of sensitivity be reduced by repeated previous iontophoresis with
Pyribenzamine to the hands, but in one instance there seems to have been an
almost complete desensitization to nickel in the patient which has lasted for more
than six months.
SUMMARY AND CONCLUSIONS
1. The mode of administration of Pyribenzamine as well as the amount ad-
ministered determine the effects of this drug. The most important factor in the
administration of antihistaminics is to deliver the drug at the reaction site in
proper concentration to be effective.
2. Oral administration of Pyribenzamine, its local injection, as well as ionto-
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phoresis reduced both the histamine wheal and flare. Pyribenzamine ointment
had little effect on the histamine reaction.
3. Reactions of epidermal sensitivity as exemplified by patch tests, were not
influenced by the oral administration of Pyribenzamine or by its local subcu-
taneous injection. Previous iontophoresis with Pyribenzamine to normal skin
would reduce such epidermal reactions at the site of the iontophoresis and for a
short distance in its vicinity.
4. Previous subcutaneous injection with novocaine or iontophoresis with
novocaine on normal skin did not reduce sensitivity reactions in the epidermis.
5. Quantitative excretion studies after application of Pyribenzamine ointment
to the unbroken skin failed to demonstrate Pyribenzamine in the urine. If any
Pyribenzamine was excreted in the urine, it must have been in insignificant and
non-detectable amounts.
6. Pyribenzamine can be demonstrated in the urine from patients on whom
Pyribenzamine ointment had been applied over areas of dermatitis. The severity
of epidermal damage plays a definite role in the amount of Pyribenzamine which
is absorbed from ointments applied to damaged skin.
7. lontophoresis over areas of normal skip allows appreciable amounts of
Pyribenzamine to be absorbed and to be demonstrated in the urine.
8. Clinical reactions of urticarial type are best treated by oral or parenteral
administration of antihistaminics. Little can be expected from the topical
applications of such drugs if they are applied to the unbroken skin.
9. Reactions of epidermal sensitivity do not lend themselves to treatment by
oral or parenteral administration of antihistaminics. It is unlikely that enough
of the drug finds its way into the epidermis from below to effect reactions in the
epidermis. Topical applications of antihistaminics readily find their way through
the damaged epidermis and seem to be the logical mode of administration of
antihistamiics for the treatment of dermatitis.
10. lontophoresis of Pyribenzamine seems practical only as a means to pro-
tect normal skin against future epidermal sensitivity reactions. This problem
requires much further study.
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DISCUSSION
Thomas Sternberg: I want to congratu'ate Dr. Peck on this interesting work.
Dr. Daniel J. Perry, Dr. Paul LeVan, and I, at the University of California at
Los Angeles, have been studying the antihistaminic drugs using histamine ionto-
phoresis. We have been using the method originally described by Cohen, Fried-
man, et al. (Journal of Allergy, 18:32, January, 1947) as modified by Perry,
Falk, and Pillsbury (Journal of Investigative Dermatology, 1:461, December,
1948). Much of our work corroborates the findings of Doctors Peck and Finkler.
Dr. Peck and Dr. Finkler indicated that there was some absorption of Pyri-
benzamine through the skin. Our preliminary studies in which varying strengths
of Pyribenzamine ointment are rubbed into the skin indicate that absorption does
take place. This is demonstrated by the lowering of the histamine-whealing
threshold. Our work has not progressed to the point where the degree of absorp-
tion can be measuied.
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The delay in the appearance of antihistaminic effect has also been evident in
our studies. Following the oral administration of the antihistaminic drugs, there
is usually a latent period of an hour before the histamine-wheal threshold is
lowered. We have also studied the effects of intravenous Pyribenzamine in 10
patients and have found that the delay in action is the same. This phenomenon
is difficult to explain but probably indicates that there is some intermediate
reaction in the body before the so-called antihistaminic effect appears.
Dr. Peck found that locally-applied Pyribenzamine resulted in a reduction
of reaction to an allergen applied over the same area. In this connection I would
like to refer to the recent work of Haley and Harris (The Journal of Pharmacology
and Experimental Therapeutics, 95:293, March, 1949). These investigators
studied the effect of antihistaminic drugs on the meso-appendix of rats. Pyri-
benzamine was perfused over the capillary bed and the resulting reaction was a
vasoconstriction which in some instances lasted for a considerable period of time.
This effect of the antihistaminic drugs may not only explain the results obtained
by Dr. Peck but may explain the mode of action of these compounds.
Dr. Walter B. Shelley: Dr. Peck's results are an excellent demonstration of
what a marvelous barrier the normal intact skin is to all compounds. Too often
we tend to forget this impermeability in our hope to achieve a dermatologic
goal, namely, to have a higher concentration of drug locally in the skin than
elsewhere.
We at the University of Pennsylvania have been interested in the relative rates
of absorption of these antihistaminic agents. We have studied 12 of the commer-
cially available antihistaminic compounds, using a technic very similar to that
used by Dr. Peck. We introduced the compounds by iontophoresis into normal
skin and assayed their presence in the skin by a histamine nuetralization test.
None of the compounds studied proved to be more effective than Pyribenzamine.
In other words, the absorption through the skin appeared to be no greater for
the other compounds than for Pyribenzamine.
Dr. II. L. Mayer: Dr. Peck's very interesting paper sheds light upon many
unexplained phenomena associated with antihistaminic therapy. First of all,
if we consider the small amounts of Pyribenzamine which are absorbed through
the skin, we are surprised by the high activity of these minute amounts. I do
not think that it is necessary to absorb very great amounts of Pyribenzamine
in order to neutralize local histamine effects. Indeed, one part of Pyribenzamine
is able to neutralize more than 100 parts of histamine. Nothing is known so far
on the fate of Pyribenzamine in the blood stream. Since it is extremely difficult
or almost impossible to trace it in the blood serum, it is possible that Pyriben-
zamine becomes bound to blood serum and then inactivated for some time. Such
an occurrence may explain Dr. Sternberg's findings. Pyribenzamine has no
immediate effects upon skin whealing, even after intravenous injections, but
only acts after a certain incubation period. Another quite important problem
is the speed of penetration of Pyribenzamine into the skin. It seems that the free
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base penetrates better and faster than the hydrochloride. In my first experiments
on the local effect of Pyribenzamine on skin sensitization, I found the activity of
free Pyribenzamine much more complete and much more rapid than that of the
hydrochloride. AU commercial ointments contain salts and although some com-
parisons have been made, it would certainly be worthwhile to resume compara-
tive clinical experiments with free and salt base.
Dr. Frederick Reiss: I appreciated greatly the excellent presentation of Dr.
Peck. It would be very simple to interpret the antipruritic effect on the so-called
allergic and itching dermatoses on the basis of anti-histaminic neutralization.
While I do not know the precise chemical differences between Thephorin and
Pyribenzamine, I do not believe there is a very profound structural difference.
However, in relation to the histamine wheat reduction using Thephorin we have
not seen the same effect as reported by Dr. Peck. With Dr. Kerm, who collabo-
rated with me, we made a definite observation, i.e., that the reflex erythema was
always prevented in our experiments. This would indicate not so much an anti-
histaminic effect of Thephorin, but a local influence on the axon reflex, which
would be more in line with the production of a local anesthesia rather than an
antihistaminic effect.
Dr. Stephen Rothman: From the point of view of percutaneous penetration
of antihistaminics in ointments it is crucial whether bases or salts are used. The
lipoid soluble base will penetrate with greatest ease whereas water soluble salts
will enter only in traces. I have been amazed to see that the marketed local
antihistaminic ointments are made up with the salts. It can be predicted that
bases wilt penetrate incomparably better and thus their antihistaminic action
will be much greater than that of salts. At the same time, however, one also can
expect "bigger and better" sensitization reactions from the bases.
I was reassured to hear that Dr. Peck definitely differentiates antihistaminic
and anti-vesiculation effects. It is inconceivable that any kind of vesicular process
is histaminic in nature. Histamine causes whealing in dilutions up to 1:20 mil-
lions, but in no concentration will it elicit blister formation. Thus the assumption
that contact dermatitis has a histaminic mechanism does not make any sense.
Dr. Sternberg's statement that Pyribenzamine has a vasoconstrictor action is a
very good explanation for the repressive action of this drug on blister formation.
Closing Discussion by Dr. Samuel M. Peck: I want to thank the discussors for
their very interesting and stimulating discussion. I plan to carry on the problem
in the directions indicated by the questions which have arisen. Concerning Dr.
Reiss' remarks that Thephorin differs markedly in its effects from Pyribeuza-
mine, you cannot compare the two. We have done a great deal of work with
Thephorin also. We cannot explain its apparent antipruritic clinical results, which
in most instances compare favorably with Pyribenzamine. I have not been able
to influence reactions to dermal sensitivity.
My conception of the contribution of Pyribenzamine to transepidermal ab-
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sorption with various modes of administration used is as follows: The histamine
reaction takes place below the epidermis, whether you give Pyribenzamine by
mouth or local injections or iontophoresis; it reaches the site of reaction and
affects it. With an ointment you get a slight effect, because only a small amount
of Pyribenzamine reaches the reaction site through the skin appendages. There
is no transepidermal absorption. With iontophoresis we have a direct epidermal
effect. In this way, reactions of both direct primary injury and sensitivity are
decreased. The amount which reaches the epidermal cell depends on how much
damage or dermatitis is present so that normal barriers are eliminated.
